IRF3

Across TCGA pan-cancer cohorts, IRF3 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated IRF3 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IRF3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IRF3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, HNSC, and COAD are the cancer types where IRF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.763	0.294	<.001	59	view →
HNSC	DFS	Quartile	II,III,IV	0.502	0.860	.001	34	view →
COAD	DFS	Median	II,III,IV	0.877	1.000	.016	30	view →
PDAC	OS	Tertile	III,IV	0.994	0.580	.004	11	view →
UCEC	DFS	Median	All	0.933	1.000	.015	10	view →
CCRCC	OS	Quartile	III,IV	0.506	0.907	.018	9	view →
LSCC	DFS	Median	All	0.885	0.980	.016	5	view →
GBM	OS	Tertile	All	0.684	0.915	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

IRF3–LUAD (DFS)

Open the LUAD breakdown →